Twin Tree Management
RPRX icon

Twin Tree Management’s Royalty Pharma RPRX Stock Holding History

Twin Tree Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,763
Closed -$1.48M – 1883
2025
Q1 		$1.39M Sell
44,763
-668
-1% -$21.2K ﹤0.01% 1210
2024
Q4 		$1.16M Sell
45,431
-29,820
-40% -$791K ﹤0.01% 1248
2024
Q3 		$2.13M Buy
75,251
+30,454
+68% +$844K ﹤0.01% 1106
2024
Q2 		$1.18M Sell
44,797
-47,128
-51% -$1.31M ﹤0.01% 1036
2024
Q1 		$2.79M Buy
+91,925
New +$2.71M 0.01% 935
2023
Q2 		– Sell
-22,367
Closed -$758K – 1479
2023
Q1 		$806K Buy
22,367
+13,397
+149% +$497K ﹤0.01% 1033
2022
Q4 		$354K Buy
+8,970
New +$374K ﹤0.01% 1129
2022
Q3 		– Sell
-36,004
Closed -$1.51M – 1650
2022
Q2 		$1.51M Buy
+36,004
New +$1.48M ﹤0.01% 1136

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Tree Management's RPRX Position: Q2 2025 in Review

Twin Tree Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 44,763 shares — an estimated $1.48M sold.

Twin Tree Management first reported a position in RPRX in Q2 2022 and held it in 8 quarters. The position peaked at $2.79M in Q1 2024. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Twin Tree Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Twin Tree Management sold 44,763 Royalty Pharma shares in Q2 2025, an estimated $1.48M.
  • Twin Tree Management first reported a position in Royalty Pharma in Q2 2022 and held it in 8 quarters.
  • Twin Tree Management's Royalty Pharma position peaked at $2.79M in Q1 2024.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Twin Tree Management's 13F filing for Q2 2025, filed 28 Jul 2025.